Continuous glucose monitoring and FGM have demonstrated efficacy in improving glycemic control and reducing hypoglycemic events in patients with type 1 diabetes mellitus (T1DM) and insulin-treated T2DM.9 However, recent studies have suggested that CGM and FGM could also play a significant, yet perhaps controversial, role in the prevention of T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.